Use of ketamines in patients refractory to conventional treatment of MDD
DOI:
https://doi.org/10.33448/rsd-v12i11.43894Keywords:
Resistant depression; Ketamines; Treatment.Abstract
Introduction: Treatment-Resistant Depression (TRD) does not have an absolute consensus on its definition, but can be understood as a severe depressive condition with an unsatisfactory response to two antidepressants from two different classes. Ketamine is a dissociative anesthetic that has an antagonistic action on glutamate/aspartate receptors, therefore, it acts in the pathophysiological condition of depression. Objective: The present study seeks to examine the particularities of the use of ketamines in people who do not improve with conventional treatments for depression. Materials and Methods: This is an integrative literature review about the role of using ketamines in patients refractory to treatment. The PICO strategy was used to prepare the guiding question. Furthermore, the descriptors “Refractory depression” were crossed; “Ketamines”; “Management”, in the National Library of Medicine (PubMed MEDLINE), Scientific Electronic Library Online (SCIELO), Ebscohost, Google Scholar and Virtual Health Library (VHL) databases. Results and Discussion: Refractory depression is serious without a clear definition. Both ketamine and electroconvulsive therapy (ECT) are considered satisfactory treatments and do not demonstrate differences in reducing suicidal ideation in these patients. Conclusion: This review highlights that for better management of ESRD it is necessary to formalize the therapeutic approach protocol for this disorder. Furthermore, it reveals that ketamines present superior results to other pharmacological measures and are very similar to ECT, but require follow-up due to the high rate of recurrence.
References
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018). Treatment-resistant depression and suicidality. Journal of affective disorders, 235, 362-367.
da Silva Mendes, L. F., de Sá Bezerra, C., Piauilino, B. C. N., de Sousa, L. L., Leal, A. K. M. P., de Sousa, P. R., & Menezes, A. G. V. A. (2023). Potencial terapêutico da cetamina em transtornos depressivos. Research, Society and Development, 12(2), e15812240153-e15812240153.
de Barros Machado, F., de Moraes Filho, I. M., Fidelis, A., de Almeida, R. J., Nascimento, M. S. S. P., & Carneiro, K. K. C. (2018). Eletroconvulsoterapia: implicações éticas e legais. Revista de Divulgação Científica Sena Aires, 7(3), 235-247.
de Melo, I. R., Oliveira, A. L. F., Lessa, V. J. C., de Farias Cavalcanti, I., Alves, M. F. T., & de Lima, F. G. P. S. (2023). Eficácia da utilização de Cetamina, Esquetamina e Midazolam para pacientes com transtorno depressivo resistente ao tratamento. Brazilian Journal of Health Review, 6(4), 18321-18330.
Dias, I. K. S., Silva, J. K. D., Gomes Júnior, S. R., Santos, T. H. N. D., & Faria, S. T. D. R. (2022). Uso da cetamina na depressão resistente ao tratamento: uma revisão sistemática. Jornal Brasileiro de Psiquiatria, 71, 247-252.
dos Santos Gonçalves, W., Lassen, R. D. H., Appolinario, J. C., & Nardi, A. E. (2022). Diagnóstico e estratégia terapêutica na depressão resistente ao tratamento. Medicina, Ciência e Arte, 1(3), 94-104.
Franco, F. M., Lima, A. J. M., Alves, N. C., Silva, R. B., & Braga, T. (2020). Os efeitos do uso da cetamina em pacientes com depressão resistente ao tratamento. Brazilian Journal of Development, 6(6), 36999-37016.
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., & Lohr, K. N. (2020). Defining treatment‐resistant depression. Depression and anxiety, 37(2), 134-145. https://doi.org/10.1002/da.22968
Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., Keilp, J. G., Moitra, V. K., Parris, M. S., & Mann, J. J. (2018). Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. American Journal of Psychiatry, 175(4), 327-335.
Guerra, C. B., Cunha, G. V., Donato, A. N. A., de Oliveira Parreira, C., Peres, P. H. M., & da Silva, D. O. F. (2019). Ketamina no manejo farmacológico agudo da ideação suicida. Revista Educação em Saúde, 7(1), 131-141.
Holsinger, T., & Riordan, P. (2023). In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response. Annals of Internal Medicine, 176(9), JC105.
Kamp, J., Jonkman, K., van Velzen, M., Aarts, L., Niesters, M., Dahan, A., & Olofsen, E. (2020). Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis. British Journal of Anaesthesia, 125(5), 750-761.
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., & Kasper, S. (2019). Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica, 139(1), 78-88.
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021). Um novo olhar para o tratamento do transtorno depressivo maior: uma revisão dos estudos clínicos realizados com cetamina e escetamina. VITTALLE-Revista de Ciências da Saúde, 33(3), 134-154.
Laguna, G. G. de C., de Carvalho, L. S., & de Azevedo, K. R. M. (2022). Eletroconvulsoterapia no manejo do risco suicida. Revista Neurociências, 30, 1–19.
Mascarenhas, A. L., Nascimento, M. C., & Passos, M. P. S. (2022). Uso da cetamina na depressão resistente ao tratamento: uma revisão integrativa. Research, Society and Development, 11(16), e16111637628-e16111637628.
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., & Mann, J. J. (2020). Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial. JAMA network open, 3(8), e2013211-e2013211.
Nogueira, D. B., de Barros Moretzsohn, J. P., Soares, L. M., de Moura Rezende, M., Oliveira, R. A. A., & Correa, C. R. (2018). O uso de cetamina no tratamento de pacientes com tendências suicidas, uma revisão integrativa. Revista interdisciplinar ciências médicas, 2(2), 57-65.
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428-438.
Teng, C. T., Caldieraro, M. A., Lacerda, A., Nardi, A., Quarantini, L., Souza, F., & Cabrera, P. (2021). Epidemiologia e ônus da depressão resistente ao tratamento no Brasil: análise do subgrupo brasileiro do estudo de observação multicêntrico TRAL. JBES-Jornal Brasileiro de Economia da Saúde.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Matheus de Oliveira Furtado; Renan Chaparro Rodrigues Alves Barbosa Coelho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
